Nosha Farhadfar, MD

ROCKSTAR data and real-world experience position belimumab as a convenient, well-tolerated option for steroid-refractory chronic GVHD, while ibrutinib use declines.

Explore 2026 steroid-refractory chronic GVHD care: four FDA-approved drugs, key trial results, and how ECP fits into real-world treatment selection.

Explore 2026 options for steroid-refractory chronic GVHD: four FDA-approved agents, key trial evidence, and where ECP fits in care.

Experts detail how steroid-refractory chronic GVHD care now uses targeted therapies and personalized choices, weighing organs, side effects, and infusion logistics.

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.